Deal with Sanofi adds two programs to GBT’s burgeoning sickle cell pipeline

With one drug on the market and a second program entering pivotal trials, GBT has augmented its pipeline of treatments for sickle cell disease by in-licensing from Sanofi two research programs that the biotech believes could complement its existing offerings.

Global Blood Therapeutics Inc. (NASDAQ:GBT) said it had obtained worldwide rights to an anti-sickling program with a novel mechanism, and a program designed to minimize inflammation and oxidative stress. Both came from Sanofi’s Bioverativ unit, which the pharma acquired in 2018...